EURONOVA - A Multicentric European Study on ProNOVA Sirolimus Eluting Stent

Prof Thomas Ischinger M D, F E S C, F A C C Munich Hospital, Germany TCT 2006

Number of patients enrolled – 300

---

Inclusion Criteria

• Patients above 18 years of age
• Denova coronary lesions ≤ 30mm
• One or multiple vessels of 2.5mm-3.5mm in diameter
• Patients who consented for the study were enrolled

---

Exclusion Criteria

• Patients with evolving MI
• Patients with prior CABG

---

Results

• Total patients enrolled - 65
• Total number of stents - 77

---

In Hospital MACE

---

6 Months MACE

---

Conclusion

Pronova stent is safe and effective in European population.